By Fineline Cube Everest Medicines Limited (HKG: 1952) announced a licensing agreement with Micot, a polypeptide NME drug developer, securing exclusive commercialization rights to MT1013 in China and the Asia‑Pacific region (excluding Japan). The first‑in‑class dual‑target peptide targets calcium‑sensing receptor (CaSR) and osteogenic growth peptide (OGP) receptor for secondary hyperparathyroidism (SHPT) treatment.
Deal Structure & Financial Terms
| Item | Detail |
|---|---|
| Licensor | Micot (polypeptide NME developer) |
| Licensee | Everest Medicines Limited (1952.HK) |
| Asset | MT1013 (dual‑target peptide) |
| Territory | China and Asia‑Pacific (excluding Japan) |
| Upfront Payment | RMB 200 million (USD 28.8 million) |
| Milestone Potential | Up to RMB 1.04 billion (USD 149 million) |
| Development Costs | Micot bears clinical development expenses |
| Clinical Stage | Phase III in China ( >50% enrolled) |
| Indication | Secondary hyperparathyroidism (SHPT) in chronic kidney disease patients on hemodialysis |
Drug Profile & Clinical Advantage
- Mechanism: Dual targeting of CaSR and OGP receptor provides fast‑acting, potent, and durable control of parathyroid hormone (PTH), calcium, and phosphorus
- Clinical Data: Phase III studies show MT1013 is well‑tolerated with potential to surpass existing therapies in comprehensive target achievement rates (iPTH, blood calcium, and phosphorus), calcification control, and cardiovascular benefits
- Market Need: SHPT affects ~50% : of dialysis patients; current therapies (cinacalcet, etelcalcetide) have limitations in efficacy and tolerability
- First‑in‑Class: First dual‑target peptide for SHPT, offering a novel mechanism of action
Market Impact & Commercial Outlook
- China SHPT Market: Valued at ¥8 billion : (~US$1.1 billion) in 2025, growing at 10% CAGR driven by expanding dialysis population
- Revenue Potential: Analysts project ¥2–3 billion (US$280–420 million) peak annual sales in China/APAC by 2028 if approved
- Strategic Value: Strengthens Everest’s metabolic and renal disease portfolio; leverages existing commercial infrastructure in dialysis centers
- Next Steps: Phase III trial completion expected H2 2026; NDA submission targeted for 2027
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, regulatory pathways, and revenue projections for MT1013. Actual results may differ due to clinical trial outcomes, competitive dynamics, and NMPA review processes.-Fineline Info & Tech